

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

SKM-1

RRID:CVCL_0098

Type: Cell Line

Proper Citation

RRID:CVCL_0098

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0098

Proper Citation: RRID:CVCL_0098

Description: Cell line SKM-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute myeloid leukemia

Defining Citation: [PMID:8136267](#), [PMID:8580805](#), [PMID:16408098](#), [PMID:20164919](#), [PMID:21989985](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27750403](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at p.Tyr327His (c.981T>C) in PubMed=8136267., Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SKM-1

Synonyms: SKM1

Cross References: BTO:BTO_0006520, CLO:CLO_0037289, EFO:EFO_0006753, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:218, BioSample:SAMN03470798, BioSample:SAMN03473113, BioSample:SAMN10988125, cancercellines:CVCL_0098, Cell_Model_Passport:SIDM00380, ChEMBL-

Cells:CHEMBL3308216, ChEMBL-Targets:CHEMBL2366085, Cosmic:787477, Cosmic:909722, Cosmic:975300, Cosmic:1012119, Cosmic:1078731, Cosmic:1465964, Cosmic:1551462, Cosmic:2131566, Cosmic:2750855, Cosmic-CLP:909722, DepMap:ACH-000373, DSMZ:ACC-547, DSMZCellDive:ACC-547, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10772-110F7, GDSC:909722, GEO:GSM482513, GEO:GSM887581, GEO:GSM888664, GEO:GSM1374880, GEO:GSM1446741, GEO:GSM1670435, GEO:GSM2124121, IARC_TP53:27238, JCRB:JCRB0118, JCRB:NIHS0147, LiGeA:CCLE_537, PharmacDB:SKM1_1418_2019, PRIDE:PXD030304, Progenetix:CVCL_0098, PubChem_Cell_line:CVCL_0098, Wikidata:Q54954746

ID: CVCL_0098

Record Creation Time: 20220427T221548+0000

Record Last Update: 20260913T010049+0000

Ratings and Alerts

No rating or validation information has been found for SKM-1.

Warning: Discontinued: JCRB; NIHS0147

Caution: TP53 mutation indicated incorrectly as being at p.Tyr327His (c.981T>C) in PubMed=8136267., Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Inthanachai T, et al. (2026) Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy. Immunology technology, 29, 101584.

Mantion CF, et al. (2025) Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities. Molecular therapy. Oncology, 33(4), 201097.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nature communications, 16(1), 7793.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell reports. Medicine, 5(6), 101572.

Ben-Crentsil NA, et al. (2024) RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. *Cancer discovery*, 14(12), 2509.

Letson CT, et al. (2023) Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(15), 2919.

Yabushita T, et al. (2023) Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. *Cell reports*, 42(9), 113098.

Rice WG, et al. (2022) Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. *Molecular cancer therapeutics*, 21(7), 1125.

Vilaplana-Lopera N, et al. (2022) Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells. *eLife*, 11.

Hernández-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.

Pallarès V, et al. (2021) Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. *Journal of controlled release : official journal of the Controlled Release Society*, 335, 117.

Hoseini SS, et al. (2021) T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. *Journal for immunotherapy of cancer*, 9(5).

Takao S, et al. (2021) Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia. *eLife*, 10.

Sivakumaren SC, et al. (2020) Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. *Cell chemical biology*, 27(5), 525.

Jin S, et al. (2020) 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 26(13), 3371.

Bai L, et al. (2019) A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. *Cancer cell*, 36(5), 498.

Fiskus W, et al. (2019) Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. *Blood cancer journal*, 9(2), 4.

Lin R, et al. (2018) The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. *Molecular cell*, 69(6), 923.

Reyna DE, et al. (2017) Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. *Cancer cell*, 32(4), 490.